Earlier this year, the FDA responded to the findings of CHOIR and several other studies by issuing a Public Health Advisory about the risks associated with erythropoiesis-stimulating agents, and introducing a black box warning to the labeling of these drugs. In this Viewpoint, Ajay K Singh responds to some of the criticisms that have been leveled at CHOIR and offers some practical advice for implementing the FDA's guidance.